Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)

Sohan Solanki, Sudipta Mukherjee, Vandana Agarwal, Raghu Thota, Kalpana Balakrishnan, Shagun Shah, Neha Desai, Rakesh Garg, Reshma Ambulkar, Nitin Bhorkar, Viplab Patro, Snita Sinukumar, Meenakshi Venketeswaran, Malini Joshi, Rajesh Chikkalingegowda, Vijaya Gottumukkala, Pascal Owusu-Agyemang, Avanish Saklani, Sanket Mehta, Ramakrishnan SeshadriJohn Bell, Sushma Bhatnagar, Jigeeshu Divatia

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Abstract

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for primary peritoneal malignancies or peritoneal spread of malignant neoplasm is being done at many centres worldwide. Perioperative management is challenging with varied haemodynamic and temperature instabilities, and the literature is scarce in many aspects of its perioperative management. There is a need to have coalition of the existing evidence and experts' consensus opinion for better perioperative management. The purpose of this consensus practice guideline is to provide consensus for best practice pattern based on the best available evidence by the expert committee of the Society of Onco-Anaesthesia and Perioperative Care comprising perioperative physicians for better perioperative management of patients of CRS-HIPEC.

Original languageEnglish (US)
Pages (from-to)972-987
Number of pages16
JournalIndian Journal of Anaesthesia
Volume63
Issue number12
DOIs
StatePublished - Dec 2019

Keywords

  • Consensus
  • cytoreduction surgical procedures
  • hyperthermia
  • induced
  • peritoneal neoplasms
  • peritoneum

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Fingerprint

Dive into the research topics of 'Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)'. Together they form a unique fingerprint.

Cite this